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ABSTRACT
Beta-2-microglobulin (B2M) is a marker of proximal tubular injury and glomerular filtration. Analyses using older/nonstandardized definitions have shown low efficacy of B2M to predict acute kidney injury (AKI). We assessed if elevated levels
of B2M would associate with either the diagnosis of AKI [under current Kidney Disease: Improving Global Outcomes (KDIGO)
criteria] or recovery from AKI. We performed a retrospective study, including children who had urine B2M (uB2M) and/or
serum B2M (sB2M) measured by immunoturbidimetry in our clinical laboratory between January 2011 and December 2015.
We defined AKI based on KDIGO criteria [increase of serum creatinine (sCr) 0.3 mg/dL over 48 h or >50% baseline over 7 days]
or urine output <0.5 mL/kg/h for 24 h. Recovery from AKI was defined as a return to baseline sCr within 6 months. We
calculated receiver operating characteristics (ROC) area under the curve (AUC). Of 529 patients, 245 developed AKI. Serum
and uB2M associated with AKI development (AUCs 0.84 and 0.73, respectively). Patients had a graded higher median sB2M
and uB2M with each higher AKI stage. sB2M differentiated Stage I from Stage III AKI (P < 0.001) and Stage II from Stage III
AKI (P ¼ 0.004). However, neither uB2M nor sB2M levels associated with recovery from AKI. Only older age {hazard ratio [HR]
0.97, [95% confidence interval (CI) 0.94–0.99]} and need for dialysis [HR 0.39 (95% CI 0.23–0.61)] predicted incomplete recovery
after AKI. Using KDIGO criteria, sB2M and uB2M associate with the severity of AKI. Given its relative ease and lower cost, we
suggest more widespread use of B2M for AKI detection.
Keywords: acute kidney injury, beta-2-microglobulin, biomarkers, pediatrics, renal recovery
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BACKGROUND

MATERIALS AND METHODS
We performed a single-center retrospective cohort study to assess if elevated levels of B2M, defined as serum levels >1.8 mg/L
or urine levels >0.2 mg/L (based on historical controls), would
diagnose AKI or predict recovery from or progression to CKD after AKI. We included all patients >1 year of age with a uB2M
and/or sB2M value determined in the St. Louis Children’s
Hospital clinical laboratory between January 2011 and
December 2015. We included patients in the outpatient clinic
and all inpatient units. B2M values in serum and urine were
assessed by immunoturbidimetry using a Cobas 6000 system
(Roche Diagnostics, Indianapolis, IN, USA). Our biomedical informatics division then gathered pertinent clinical laboratory
data from our electronic medical record, which was then reviewed
and verified by one study team member (Kevin T. Barton). We
gathered data on baseline sCr (lowest value 3 months prior to B2M
lab draw when available), sCr at the time of B2M lab draw, maximum sCr during admission, sB2M, uB2M, urine protein, urine creatinine, urine output and percent fluid overload over 24–48 h prior
to B2M lab draw. We also identified any past history of CKD, diagnosis on admission, lengths of hospital stay, ICU admission and
length of stay and recovery from AKI. This study was approved by
the institutional review board.
Using the KDIGO creatinine definition of AKI, we identified
patients who met the KDIGO sCr definition of AKI and its stages.
We used modified urine criteria of urine output <0.5 mL/kg/
h over 24 h, as charting in smaller time periods was incomplete.
Patients <1 year of age were excluded due to a lack of normative
values for B2M in this population at the time of the study.
Recovery was defined as a return to baseline sCr within
6 months of AKI. Time to recovery and degree of recovery were
recorded—complete or incomplete. If there was incomplete recovery, the stage of CKD was defined per standard criteria [15].
For comparisons between the AKI and no AKI groups, age
was analyzed using a Wilcoxon rank sum test and categorical
variables were analyzed using a chi-square test or Fisher’s exact
test, as appropriate. The sB2M and uB2M measures were analyzed using nonparametric approaches (Kruskal–Wallis and
Wilcoxon rank sum) to test for differences among AKI groups
and stages. The ability of sB2M and uB2M to predict AKI diagnosis was assessed using an ROC curve and the AUC statistic.
Univariable association of covariates with time to recovery from
AKI was analyzed using Cox regression analysis. Patients that
did not recover were censored at the most recent follow-up date
available in the database (date of lab draw up to 6 months after
hospital discharge or date of death). P-values <0.05 were considered significant.

RESULTS
Demographic characteristics
A total of 637 charts had available sB2M or uB2M results available in the study time period; 529 patients were >1 year of age
(Figure 1). Of these 529 244 total patients met the KDIGO
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Acute kidney injury (AKI) often occurs in hospitalized patients
and is associated with increased morbidity and mortality [1]. The
incidence of AKI varied considerably in the past, partly due to the
use of many different definitions using variations of either serum
creatinine (sCr), urine output or need for dialysis [2, 3].
Standardized definitions and staging such as Risk, Injury, Failure,
Loss, End-stage renal disease (RIFLE) and the AKI Network (AKIN)
were recently merged into the current consensus Kidney Disease:
Improving Global Outcomes (KDIGO) definitions and staging [2,
4]. The Acute Kidney Injury–Epidemiologic Prospective
Investigation study was a multination cross-sectional study that
recently described the epidemiology of AKI in hospitalized adults
in 97 intensive care units (ICUs) from 33 different countries. Using
the KDIGO criteria, the overall incidence of AKI was 57% with
>30% developing KDIGO Stage III AKI [1]. Furthermore, AKI conferred a clearly increased risk of chronic kidney disease (CKD) [estimated glomerular filtration rate (eGFR) at hospital discharge of
57 with AKI versus 95 without AKI; P < 0.001) and mortality (27%
with AKI versus 7% without AKI; P < 0.001) [1]. The incidence of
AKI in critically ill pediatric patients was recently reported as
23.6% by the Assessment of Worldwide Acute Kidney Injury,
Renal Angina and Epidemiology (AWARE) trial using the current
KDIGO standard definition [5]. They reported 11% mortality for
those with severe AKI (KDIGO Stage II or III) and found that severe
AKI increased the risk of death [odds ratio (OR) 1.77] [5]. Most importantly, sCr alone failed to identify AKI in 18% of patients with
low urine output [3, 5, 6].
sCr, the historical surrogate for kidney function, used in the
RIFLE, AKIN and KDIGO classifications, does not increase until
significant kidney injury has already occurred. In pediatrics,
moreover, sCr levels change with age. Creatinine is falsely low
in children with chronic illness whose muscle mass is well below normal, further complicating a creatinine-based AKI definition. Due to the imprecision of creatinine, multiple serum and
urine biomarkers have been investigated over the past decade
[7, 8].
Beta-2-microglobulin (B2M, molecular weight 12 000 Da) is a
component of the major histocompatibility antigen. By coupling
with the neonatal Fc receptor, it helps regulate serum levels of
immunoglobulin G, albumin and hepcidin [9]. It is hence implicated in a multitude of disease processes, including glomerulonephritis, AKI and iron overload diseases. B2M is filtered at the
glomerulus and 99.9% is reabsorbed by the proximal tubule.
B2M allows for functional assessment of both the glomerulus
and the renal tubules. In the 1980s, multiple studies analyzed
the ability of B2M to assess kidney function and found it in
most cases superior to sCr [10–12]. For the diagnosis of AKI, using older, nonstandardized definitions, Herget-Rosenthal et al.
[13] found that urine B2M (uB2M) performed poorly at predicting
the need for renal replacement therapy [area under the curve
(AUC) 0.51]. Under modified pediatric RIFLE (pRIFLE) criteria, Du
et al. [14] studied B2M and reported a low receiver operating
characteristics (ROC) curve AUC of 0.59 [14].
To date, B2M has not been studied using KDIGO criteria or
evaluated as a marker for kidney recovery or progression to
CKD after AKI. At our center we have routinely used B2M as a
marker for the diagnosis of AKI and monitoring kidney function
in children with CKD. We have used B2M both in outpatient
clinics to monitor patients recovering from AKI and to assess
for AKI in hospitalized patients. For outpatients, uB2M is used
more frequently to assess tubular function while using creatinine only for glomerular function. For inpatients, both uB2M

and serum B2M (sB2M) are used when possible, but this is limited in patients with anuric AKI. The aims of this study were to
compare B2M levels (serum and urine) between patients with
and without AKI (as defined by KDIGO) and determine the ability of elevated B2M levels to discriminate between AKI stages
and to assess the relationship between B2M elevation and recovery or progression to CKD after AKI.

Beta-2-microglobulin associates with KDIGO AKI
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FIGURE 1: Consort style flow diagram.

definition of AKI and 285 patients had sB2M and/or uB2M testing but did not meet the KDIGO definition of AKI.
There was a significant difference in age between the AKI
and no AKI groups (median 14.29 versus 9.89 years; P < 0.001;
Table 1). There was no difference between groups based on
race, gender or those with preexisting CKD. The most common
diagnosis was medication toxicity (n ¼ 56) followed by primary
renal disease and dehydration (Table 1). There was a significant
difference between groups in percentages of heart transplant
recipients (P < 0.03 and P < 0.001), solid organ transplants overall
(P < 0.001), bone marrow transplant recipients (P ¼ 0.004), viral
illness (P ¼ 0.002) and sepsis (P < 0.001). There was no significant
association between AKI and time from transplant, suggesting a
more diverse range of causes than chronic medication/calcineurin toxicity. In patients who received a solid organ transplant, the most common causes for AKI were medication
toxicity, dehydration and cardiac dysfunction. However, there
was not a significant difference between those with and without AKI (Table 2).

Male, n (%)
Race, n (%)
Caucasian
African American
Other
Diagnosis, n (%)
Medication toxicity
Primary renal disease
Dehydration
Solid organ transplant
Sepsis
Bone marrow transplant
Cardiac dysfunction
UTI
Viral illness
Prematurity
Other
Lung transplant
Liver transplant
Heart transplant
Kidney transplant

AKI
(n ¼ 244)

No AKI
(n ¼ 285)

14.29
(9.36–17.18)
120 (49.2)

9.89
(3.92–15.93)
145 (50.9)

169 (69.6)
56 (23.1)
18 (7.4)

204 (71.6)
67 (23.5)
14 (4.9)

0.49

56 (23.0)
47 (19.3)
50 (20.5)
41 (16.8)
37 (15.2)
21 (8.6)
33 (13.5)
11 (4.5)
26 (10.7)
3 (1.2)
111 (45.5)
21 (8.6)
6 (2.5)
16 (6.6)
3 (1.2)

20 (7.0)
86 (30.2)
19 (6.7)
22 (7.7)
9 (3.2)
8 (2.8)
15 (5.3)
11 (3.9)
11 (3.9)
5 (1.8)
162 (56.8)
13 (4.6)
5 (1.8)
3 (1.1)
2 (0.7)

<0.001
0.004
<0.001
0.001
<0.001
0.004
0.001
0.71
0.002
0.73
0.009
0.06
0.57
<0.001
0.67

P-value
<0.001
0.73

Table 2. Association between diagnosis and AKI in solid organ transplant patients
Variable
Medication toxicity, n (%)
Dehydration, n (%)
Cardiac dysfunction, n (%)

AKI (n ¼ 41)

No AKI (n ¼ 22)

P-value

12 (29.3)
12 (29.3)
9 (22.0)

2 (9.1)
1 (4.6)
2 (9.1)

0.11
0.024
0.30

Need for renal replacement therapy
Both uB2M and sB2M were associated with a need for renal replacement therapy. For this analysis we used all patients, not
just those with both uB2M and sB2M values, to account for anuric patients (Table 7).

Prediction of AKI
Serum and urine B2M were both strongly associated with AKI
development, with an AUC of 0.84 and 0.73, respectively
(Figure 2). The median values for sB2M and uB2M were significantly higher in the AKI group versus the no AKI group (Table 3).
We analyzed patients who had both uB2M and sB2M values and
the results were nearly identical to when we included patients
who had only uB2M or sB2M. We only included analyses for
patients who had both uB2M and sB2M values. By the Kruskal–
Wallis test, patients also had a graded higher and significantly
different median sB2M and uB2M with each higher AKI stage
(Tables 3 and 4). Pairwise comparisons among stages revealed
that sB2M and uB2M differentiated between no AKI and Stage II
or III AKI (P < 0.001; Tables 4 and 5). sB2M also differentiated between no AKI and Stage I AKI (P < 0.001), Stages I and II AKI
(P < 0.001) and Stages II and III AKI (P ¼ 0.004; Table 4). Although
there is literature supporting uB2M as a specific marker for
drug-induced AKI, we found no statistically significant difference in our population (Table 6).

Recovery from AKI
Of those 245 patients with AKI, our results showed 172 patients
had complete recovery, with 73 patients developing CKD or
death (66 CKD, 4 chronic dialysis, 12 died, not mutually exclusive). Cox regression analysis indicated that older age and need
for dialysis were the only variables that were significantly associated with a greater risk of not recovering after AKI {hazard ratio [HR] 0.967 [confidence interval (CI) 0.941–0.993] and 0.388 (CI
0.233–0.610), respectively; Table 8}. Neither uB2M nor sB2M was
associated with the time-to-recovery outcome.

DISCUSSION
Our study highlights the ability of sB2M to identify patients
with AKI to a high degree of accuracy, using the newer and current standardized and consensus KDIGO definition. Serum B2M
also showed a graded increase with increasing severity of AKI.
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FIGURE 2: ROC curves for sB2M and uB2M versus AKI.

Table 3. sB2M and uB2M versus AKI
Variable
sB2M (mg/L)
uB2M (mg/L)

AKI, median (IQR)

Table 6. uB2M versus drug-induced AKI
No AKI, median (IQR)

4.4 (2.8–9.4)
3.9 (0.4–17.3)

1.9 (1.4–2.6)
0.2 (0.2–2.9)

P-value
<0.001
<0.001

Table 4. Nonparametric analyses of sB2M and AKI stages

Group comparison
No versus Stage I
No versus Stage II
No versus Stage III
Stage I versus Stage II
Stage I versus Stage III
Stage II versus Stage III

Variable
uB2M (mg/L)

Drug-induced AKI,
median (IQR)

AKI (other causes),
median (IQR)

P-value

3.5 (0.3–18.0)

3.1 (0.4–16.0)

0.92

Table 7. sB2M and uB2M versus dialysis (within AKI)

Group 1,
median (IQR)

Group 2,
median (IQR)

P-value

Variable

Dialysis,
median (IQR)

No dialysis,
median (IQR)

P-value

1.9 (1.4–2.6)
1.9 (1.4–2.6)
1.9 (1.4–2.6)
3.1 (2.2–5)
3.1 (2.2–5)
3.8 (2.6–7.4)

3.1 (2.2–5)
3.8 (2.6–7.4)
5.7 (3.7–10.1)
3.8 (2.6–7.4)
5.7 (3.7–10.1)
5.7 (3.7–10.1)

<0.001
<0.001
<0.001
0.14
<0.001
0.004

uB2M (mg/L)
sB2M (mg/L)

9.5 (0.7–29.9)
8.5 (5.5–14.2)

2.6 (0.3–15.2)
3.9 (2.7–8.3)

0.043
<0.001

Table 5. Nonparametric analyses of uB2M and AKI stages

Group comparison

Group 1,
median (IQR)

Group 2,
median (IQR)

P-value

No versus Stage I
No versus Stage II
No versus Stage III
Stage I versus Stage II
Stage I versus Stage III
Stage II versus Stage III

0.2 (0.2–2.9)
0.2 (0.2–2.9)
0.2 (0.2–2.9)
1.5 (0.2–13.6)
1.5 (0.2–13.6)
8 (0.4–22.7)

1.5 (0.2–13.6)
8 (0.4–22.7)
3.7 (0.6–16.8)
8 (0.4–22.7)
3.7 (0.6–16.8)
3.7 (0.6–16.8)

0.028
<0.001
<0.001
0.06
0.10
0.44

Urine B2M was also able to identify patients with AKI, but with
slightly less accuracy than sB2M. Neither uB2M nor sB2M were
significantly associated with recovery from AKI. Our study
showed that recovery was less likely in children who were older

or requiring renal replacement therapy during their AKI. These
results most likely reflect accumulation of nephrotoxicity from
chronic diseases such as congenital heart disease or refractory
malignancy in addition to their treatment regimes.
The ideal renal biomarker should have a regular production
rate and be eliminated only via glomerular filtration, without
tubular secretion or reabsorption. Creatinine has multiple limitations as a biomarker, including tubular secretion and its dependence on the patient’s muscle mass, age or gender. Most
importantly, it is a late and nonspecific marker of injury [16].
Our results show that B2M is strongly associated with AKI in
the pediatric population. Using KDIGO criteria versus pRIFLE criteria, the AUC improved dramatically from the previously
reported 0.59 to our value of 0.84 for sB2M and 0.73 for uB2M.
Serum B2M was statistically significantly different between almost all stages of AKI, making it a potentially useful tool for estimating the functional severity of AKI. The uB2M values
peaked at Stage II AKI and decreased at Stage III, likely due to
decreased urine output in that group, limiting its utility at severe stages of AKI. The higher AUC for sB2M compared with
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Table 8. Univariable time to event associations of covariates for likelihood of complete recovery from AKI
Variable

P-value

0.967 (0.941–0.993)
0.999 (0.998–1.001)
0.991 (0.939–1.035)
1.003 (0.998–1.008)
0.984 (0.945–1.021)
1.11 (0.439–1.966)
1.158 (0.857–1.567)
0.755 (0.533–1.088)
0.907 (0.468–1.64)
0.616 (0.33–1.052)
0.832 (0.613–1.125)
0.761 (0.481–1.15)
0.62 (0.306–1.115)
0.388 (0.233–0.61)
0.698 (0.356–1.229)
2.515 (0.886–5.579)
0.833 (0.435–1.444)
0.94 (0.053–4.228)

0.01
0.39
0.72
0.23
0.41
0.79
0.34
0.30
0.08
0.23
0.20
0.12
<0.001
0.23
0.08
0.54
0.95

a

Reference group for race was African American.

uB2M is likely due to some prerenal AKI cases being classified
as Stage I KDIGO AKI, as would be expected.
To our knowledge, this is the first study to analyze B2M as a
marker for AKI under a standardized KDIGO definition. Previous
studies have analyzed multiple biomarkers using nonstandardized or older definitions or specific populations. Du et al. [14], for
example, studied patients presenting to an emergency department using pRIFLE criteria, with an AUC of 0.59 for uB2M. They
also examined neutrophil gelatinase-associated lipocalin (NGAL),
interleukin-18 and kidney injury molecule 1 (KIM-1), which all
had AUC values ranging from 0.44 to 0.66, comparable with B2M.
Compared with other newer biomarkers being developed, the
AUC of sB2M in mixed-etiology AKI populations compares favorably with the AUCs of the newer biomarkers in similar mixed-etiology populations, which range from 0.61–0.96 for NGAL to 0.69–
0.85 for KIM-1 and 0.70–0.75 for L-type fatty acid binding protein
(L-FABP) [8]. In the Translational Research Investigating
Biomarker Endpoints in AKI study, investigators found urine
NGAL, L-FABP and KIM-1 to be highly accurate markers of Stages
II and III AKI in pediatric cardiac surgery patients (AUC 0.75, 0.77
and 0.70, respectively), where the exact time of injury is known
and the type of injury is predominantly ischemic, thus biomarkers tend to be more accurate [17]. Furthermore, sB2M can be
used for all hospitalized patients and not just those who are critically ill. However, we have not tested B2M versus the other biomarkers head to head using common KDIGO criteria.
Although we found a significant association between uB2M
and sB2M with the need for renal replacement therapy, there
was significant overlap in B2M values between those who did
and did not need renal replacement therapy. The utility of B2M
as a predictor of renal replacement therapy is therefore limited,
but warrants further study.
Neither sB2M nor uB2M were significantly associated with
recovery from AKI, which may be due to the retrospective nature of this study. Although there are consensus definitions for
recovery in adults, there is currently no corresponding definition of renal recovery after AKI in the pediatric population [18].
Most longitudinal follow-up studies are limited to dialysis requirement or transplant, largely ignoring the early stage of CKD.

FIGURE 3: Box plots of sB2M and uB2M versus AKI.

One report describes 34% of patients with residual CKD or
dialysis dependence after AKI [19]. More importantly, at the 3to 5-year follow-up, 60% of those patients who did completely
recover went on to develop signs of CKD, including proteinuria,
hypertension or decreased GFR [19]. This study highlights the
importance of longitudinal follow-up in patients with AKI, even
with apparent full recovery. Some of the newer biomarkers
such as NGAL, KIM-1 and L-FABP have moderately high AUCs of
0.67–0.82 for prediction of a composite outcome of AKI progression, dialysis or death in either cardiac bypass or mixed-etiology
critically ill populations [8]. To our knowledge, AUC data for the
isolated outcome of less than complete recovery from AKI in
mixed-etiology critically ill patients is not available for these
newer biomarkers.
There were multiple limitations to this study. Due to the
multifactorial nature of the causes of AKI, it is difficult to study
direct causality. As a retrospective chart analysis, there is always the possibility of missing or inaccurate data. Inherent in
our study also is a selection bias for patients who are likely to
have significant kidney injury and/or kidney disease and therefore had B2M tested. AKI in the neonatal population has new
criteria that were standardized after the completion of data collection. We analyzed B2M versus AKI in this population and
subjectively it showed no difference between those with and
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without AKI and a wider range of values in those without AKI
(Figure 3). This may be due to the maturation of tubular function
in this population. A future study could analyze this population
controlling more specifically for age and prematurity.
In addition, the timing of B2M draws was mostly at the time
of initial recognized elevated creatinine, but the exact timing
was inconsistent. We also only analyzed single measurements
of B2M per patient. In the future, serial measurements could
help clarify the role of B2M as a predictor of AKI and recovery
from AKI. Our lab does not adjust the pH of urine samples,
which may have affected our uB2M results. Furthermore, we
had to modify KDIGO urine output criteria, which may have
misidentified some early AKI as no AKI. However, using a longer
time period of decreased urine output would decrease the number of Stage I AKI patients detected, increasing the overall severity of the cohort. For recovery data, some patients were lost to
follow-up and were assumed to have not recovered, which may
not have been true.
B2M, while a better biomarker than creatinine, still has limitations. It is increased in hematologic malignancies and multiple autoimmune diseases such as Crohn’s disease and Sjögren’s
syndrome and, importantly, lupus erythematosus. Despite
these limitations, B2M still showed high AUC values for the prediction of AKI.
Multiple biomarkers have been identified and continue to be
studied in an attempt to identify AKI earlier and more accurately to improve treatment and outcomes. We have shown
that B2M is a good predictor of AKI, but not necessarily specific
to the severity of AKI. Most importantly, with a unified definition through KDIGO criteria, we have shown B2M to be better at
predicting AKI development than has been previously reported.
With its relatively low cost ($2.45/test at our center) and potentially wider clinical availability, we suggest B2M be implemented more widely as a functional biomarker for AKI.

